In this episode our hosts Jason Yeh, PharmD (US Transplant MSL) and Katie McMurry, PharmD (US Transplant MSL) have a conversation with Dr. Sagar Patel, an Assistant Professor in the Transplant and Cellular Therapy Program at the Huntsman Cancer Institute in Salt Lake City, Utah. In this episode, Dr. Patel discusses current transplantation barriers observed in the diagnosis and treatment of chronic graft versus host disease, the existing tools utilized to improve outcomes and potential innovations to mitigate barriers. 

This program is non-promotional and sponsored by Sanofi.  Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program.  This program does not constitute an endorsement by Sanofi of any particular organization or its programming.  Additional resources and information may be available and should be investigated. 

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

In this episode our MSL co-hosts Yiota Manolopoulos, PharmD, MPH and Katie Mousavi, PharmD have a conversation with Anne Peters, MD on how to incorporate social determinants of health in clinical trials and methods to overcome the challenges that under resourced communities face daily. Dr. Peters identifies key barriers that physicians and other healthcare providers encounter when designing clinical trials for patients with diabetes, particularly among racial and ethnic minority populations and other marginalized communities. We conclude the episode with concrete actions and resources our listeners can use to design clinical trials, ensure longevity of these interventions, and begin to narrow the gap on healthcare disparities within the racial and ethnic minority populations with diabetes.

This program is non-promotional and sponsored by Sanofi. The presenter was compensated by Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

Supporting literature from episode:

1. Social Determinants of Health at CDC: https://www.cdc.gov/about/sdoh/index.html
2. Social Determinants of Health and Diabetes: A Scientific Review: https://doi.org/10.2337/dci20-0053
3. The multidisciplinary team in diagnosing and treatment of patients with diabetes and comorbidities: A scoping review: https://doi.org/10.1177/26335565231165966

Music: Spark of Inspiration by Shane Ivers - https://www.silvermansound.com

Despite having a lower reported prevalence of atrial fibrillation, contemporary data suggest underrepresented racial and ethnic populations experience disparities in atrial fibrillation treatment and health outcomes. Join our MSL co-hosts Dalila Masic, PharmD and Teresa Russell, PharmD as they have a conversation with Larry R. Jackson, II, MD, MHSc. What does the literature show about atrial fibrillation detection, management, and outcomes in underrepresented populations with atrial fibrillation? How can clinicians partner with patients to help bridge these gaps? Dr. Jackson shares his insights from years of clinical experience and research on health equity and racial/ethnic differences in arrhythmia care.

This program is non-promotional and sponsored by Sanofi. The presenter was compensated by Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

Resources mentioned in episode:

1. American College of Cardiology CardioSmart Tools: https://www.cardiosmart.org/topics/atrial-fibrillation

2. Healthwise Shared Decision Making Tools: https://www.healthwise.org/solutions/care-transformation.aspx

Supporting literature from episode:

1. Racial and Ethnic Considerations in Patients with Atrial Fibrillation: JACC Focus Seminar 5/9: https://pubmed.ncbi.nlm.nih.gov/34887142/

2. Racial/Ethnic Differences in Atrial Fibrillation Symptoms, Treatment Patterns, and Outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry: https://pubmed.ncbi.nlm.nih.gov/26995367/

3. Differences by Race/Ethnicity in the Prevalence of Clinically Detected and Monitor-Detected Atrial Fibrillation: MESA: https://pubmed.ncbi.nlm.nih.gov/31934795/

4. Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities: https://pubmed.ncbi.nlm.nih.gov/34238436/

5. Under-Reporting and Under-Representation of Racial/Ethnic Minorities in Major Atrial Fibrillation Clinical Trials: https://doi.org/10.1016/j.jacep.2020.03.001

6. Racial and Ethnic Disparities in Arrhythmia Care: A Call for Action: https://pubmed.ncbi.nlm.nih.gov/35842408/

Music: Spark of Inspiration by Shane Ivers - https://www.silvermansound.com